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Abstract: Inflammatory granulocytes are characterized by an oxidative burst, which may promote
oxidative stress and lipid modification both in affected tissues and on a systemic level. On the
other hand, redox signaling involving lipid peroxidation products acting as second messengers of
free radicals play important yet not fully understood roles in the pathophysiology of inflammation
and various stress-associated disorders. Therefore, the aim of this study was to evaluate the onset
of oxidative stress and alterations of enzyme-dependent lipid metabolism resulting from redox
imbalance in granulocytes and plasma obtained from patients with psoriasis vulgaris or psoriatic
arthritis in comparison to the healthy subjects. The results obtained revealed enhanced activity of
pro-oxidant enzymes nicotinamide adenine dinucleotide phosphate (NADPH) and xanthine oxidases
in granulocytes with a decrease of enzymatic and non-enzymatic antioxidants in the plasma of
psoriatic patients. The nuclear factor erythroid 2–related factor 2 (Nrf2) and its regulators were
increased in both forms of psoriasis while heme oxygenase 1 levels were increased only in psoriasis
vulgaris. The redox imbalance was associated with decreased levels of phospholipids and of free
polyunsaturated fatty acids but with enhanced activity of enzymes involved in lipid metabolism
(phospholipase A2, acetylhydrolase PAF, cyclooxygenases 1 and 2) and increased lipid peroxidation
products 4-hydroxynonenal, isoprostanes, and neuroprostanes. Increased endocannabinoids and
G protein-coupled receptor 55 were observed in both forms of the disease while expression of the
cannabinoid type 1 receptor (CB1) was increased only in patients with psoriatic arthritis, which is
opposite to the cannabinoid type 2 receptor. This receptor was increased only in psoriasis vulgaris.
Changes in protein expression promoted the apoptosis of granulocytes by increased caspases mainly
in psoriasis vulgaris. This study indicates that inhibition of the Nrf2 pathway in psoriatic arthritis
promotes a redox imbalance. In addition, increased expression of CB1 receptors leads to increased
oxidative stress, lipid modifications, and inflammation, which, in turn, may promote the progression
of psoriasis into the advanced, arthritic form of the disease.
Keywords: psoriasis; arthritis; inflammation; granulocytes; redox signaling; oxidative stress; lipid
peroxidation; 4-hydroxynonenal; lipids; endocannabinoid system
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1. Introduction
Under physiological conditions, cells are in a stable state of redox homeostasis, which is
maintained by the balance between continuous production of reactive oxygen species (ROS) and
antioxidant activities [1]. Interactions between ROS and antioxidants produce metabolic responses to
endogenous and/or exogenous signals/stressors. These signals trigger and modulate the appropriate
adaptation processes or activation of the mechanisms causing cellular decay [2]. Therefore, cellular
redox homeostasis plays a key role in physiology of the cell as well as in numerous pathophysiological
processes. Elevated ROS levels that cannot be counteracted by the cellular antioxidant abilities induce
a redox imbalance that leads to oxidative stress [1,3], which further causes oxidative modifications in
the structure and function of cellular components especially of the unsaturated bio-membrane lipids [4].
The consequence is an increase of the products of ROS-dependent oxidative fragmentation as well
as cyclization of fatty acids [5,6]. Among them, reactive aldehydes, which are products of oxidative
fragmentation, may act as second messengers of free radicals and regulatory signaling molecules
that modify cellular metabolism and may cause death either through necrosis or apoptosis [7].
Additionally, lipids can also undergo enzymatic transformation involving enzymes like phospholipases,
cyclooxygenases, or lipoxygenases, which generates a large group of lipid mediators [8]. This may show
pro-inflammatory or anti-inflammatory properties. Among these, endocannabinoids and leukotriene
B4 (LTB4) are known as pathophysiological activators of granulocytes [9]. Endocannabinoids are
agonists of G protein-dependent cannabinoid receptors such as CB1 or CB2 and receptors belonging
to the TRPVs and GRPs groups whose activation modifies the level of ROS and pro-inflammatory
mediators [10,11]. Activation of CB1 receptors stimulates the generation of ROS and TNF-α while
CB2 and TRPV1 receptors have anti-inflammatory activity and contribute to the reduction of ROS
levels [10,11]. Additionally, one of the main endocannabinoids, 2-AG, is directly able to impair
both inflammation as well as oxidative stress, which is often considered to be a compensatory or
adaptive mechanism [12]. Thus, changes in the endocannabinoid system may model oxidative stress
and the inflammatory processes. This is supported by the fact that, among inflammatory diseases,
those accompanied by acute or chronic oxidative stress exhibit higher levels of endocannabinoids [13].
Accordingly, it was suggested that endocannabinoids play a role in the pathogenesis of obesity,
atherosclerosis, and diabetes, which are all comorbidities associated with psoriasis.
Psoriasis is a chronic, inflammatory disease manifested by the presence of skin lesions associated
with hyper-proliferation and impaired apoptosis of keratinocytes. The disease is not only manifested
by skin changes but also by systemic abnormalities like enhanced activation of leukocytes and higher
levels of cytokines [14,15]. Moreover, there is a significant increase in granulocyte levels in the
blood of patients with psoriasis [16]. Activated granulocytes especially neutrophils are characterized
by the overproduction of ROS, which is denoted as an oxidative burst. Therefore, in many cases,
their enhanced activation in the course of inflammation correlates with the intensity of oxidative stress,
which is an important pathophysiological factor of inflammatory, stress-associated diseases [17–21]
while alterations of antioxidants are associated with psoriasis [15]. In addition, it is suggested that
oxidative stress may activate mechanisms that restore the redox balance including activation of the Nrf2
transcription factor, which is responsible for antioxidant and cyto-protective gene transcription [22,23].
However, a reduction in Nrf2 activity was observed in the skin of psoriatic patients [24].
Psoriasis occurs most often in two forms: as psoriasis vulgaris and as psoriatic arthritis with
different clinical courses. At the same time, biochemical and metabolic differences between the two
forms are not well investigated [15]. So far, there are no studies assessing possible interrelations
between oxidative stress parameters, inflammatory processes, and the endocannabinoid system in
patients with psoriasis. Therefore, the aim of this study was to compare the relationship between the
redox balance and the endocannabinoid system with pro-inflammatory factors in granulocytes and
the plasma of healthy people and the plasma of patients with psoriasis. In addition, the molecular
mechanisms of the development of two different forms of psoriasis vulgaris (Ps) and psoriatic arthritis
(PsA) will be compared.
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2. Materials and Methods
The blood samples were collected from a group of 68 patients (32 women and 36 men) with
a mean age of 38.2 years (range 17–66 years of age) with a diagnosis of psoriasis vulgaris for at least
6 months with at least 10% of the total body surface area affected. The other group was comprised of
34 patients (15 women and 19 men) and their mean age was 37.7 years (range 14–67 years of age) with
a diagnosis of psoriatic arthritis. The control group consisted of 34 healthy subjects (15 women and
19 men) with an average age of 37.9 years old (range 20–64 years of age). None of the patients or healthy
subjects had received topical or oral medications during the 4 weeks before the study. While taking the
history of disease of each patient, particular attention was given to current use of certain medications
(anticoagulants and antiplatelet drugs) and comorbidities (liver, kidneys, or cardiovascular diseases,
cancer, respiratory disorders, and diabetes). Hence, individuals whose case history indicated any
chronic or acute disorder that might affect the analyses were excluded from the study. None of the
participants were smokers. The study was approved by the Local Bioethics Committee in the Medical
University of Bialystok (Poland), No. R-I-002/289/2017. Written informed consent was obtained from
all the patients.
Blood samples were taken into ethylenediaminetetraacetic acid (EDTA) tubes and a two-stage
centrifugation was carried out. In the first stage, the sample was centrifuged at 3000× g (4 ◦C) to
obtain the plasma and the buffy coat. Granulocytes were isolated from the buffy coat by gradient
centrifugation using Gradisol G (Aqua-Med ZPAM–KOLASA, Łódz´, Poland) Samples were layered
on Gradisol and subjected to 25 min centrifugation at 300× g at room temperature. The individual
cell fraction was collected, washed, and re-suspended in PBS containing a proteasome inhibitor mix.
An antioxidant-butylhydroxytoluene (BHT) was added to plasma and granulocyte samples before
storing them to prevent oxidation. Samples were stored at –80 ◦C until analysis.
2.1. Pro-Oxidant Parameters
NADPH oxidase (NOX—EC 1.6.3.1) activity was measured in granulocytes using the
lucigenin-enhanced chemiluminescent method. Enzyme specific activity was expressed in RLU
(Relative Luminescence Units) per microgram of proteins [25].
Xanthine oxidase (XO—EC 1.17.3.2) activity was determined in granulocytes as the rate of uric
acid generation from xanthine detecting at a wavelength of 292 nm [26]. One unit of XO activity was
defined as 1 µmol uric acid produced per min at 37 ◦C. Obtained data were normalized to 1 milligram
of protein.
2.2. Antioxidant Parameters
2.2.1. Determination of Protein Antioxidants
Plasma glutathione peroxidase (GSH-Px—EC.1.11.1.6) activity was measured spectrophotometrically
using the method of Paglia and Valentine [27]. GSH-Px activity was assayed by measuring the conversion
of NADPH to NADP+. One unit of GSH-Px activity was defined as the amount of enzyme catalyzing the
oxidation of 1 µmol NADPH per min at 25 ◦C and a pH of 7.4. Enzyme specific activity was expressed in
units per mg of protein.
Plasma glutathione reductase (GSSG-R—EC.1.6.4.2) activity was measured spectrophotometrically,
according to the method of Mize and Longdon [28] by monitoring the oxidation of NADPH at 340 nm
at pH 7.4. One unit of GSSG-R oxidized 1 µmol of NADPH/min at 25 ◦C and pH 7.4. Enzyme activity
was expressed in units per mg of protein.
Plasma superoxide dismutase (Cu/Zn–SOD—EC.1.15.1.1) activity was determined
spectrophotometrically, according to the method of Misra and Fridovich [29]. One unit of
SOD was defined as the amount of the enzyme, which inhibits epinephrine oxidation to adrenochrome
by 50%. Enzyme specific activity was expressed in units per mg of protein.
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Thioredoxin reductase (TrxR—EC.1.8.1.9) activity in granulocytes was estimated using
a commercial assay kit (Sigma-Aldrich, St. Louis, MO, USA). The assay was based on reduction
of 5,5′-dithiobis(2-nitrobenzoic) acid by NADPH to 5-thio-2-nitrobenzoic acid, which was estimated by
a colorimetric measurement at 412 nm [30]. Obtained data were normalized to 1 milligram of protein.
The Thioredoxin (Trx) level in granulocytes was quantified by using the ELISA method [31]. ELISA
plates with samples were incubated overnight with a primary antibody against thioredoxin (Abcam,
Cambridge, MA, USA) and for 1 h with secondary goat anti-rabbit antibody (Dako, Carpinteria, CA,
USA). As a chromogen, 0.1 mg/mL TMB in citric buffer with 0.012% H2O2 was added. The reaction
was stopped by sulfuric acid and absorption was read at 450 nm. The Trx level was normalized for
milligrams of protein.
2.2.2. Nrf2 Pathway Parameters
The expression of Nrf2 pathway parameters such as Nrf2, Keap1, Bach1, KAP1, p62, p21, and HO-1
was estimated using Western blot analysis (details are given below).
2.2.3. Determination of Low Molecular Antioxidants
Reduced GSH content in plasma was measured according to the procedure of Maeso by
using capillary electrophoresis [32]. The separation was performed on a fused-silica capillary
(75 µm (i.d.) × 30 cm (total length)/10 cm (length to detector)) with a spectrophotometer detection
at 200 nm.
The vitamins C [10] as well as vitamins A and E [11] in the plasma were determined by the HPLC
methods with spectrophotometric detection at 250 nm and 294 nm, respectively.
2.3. Phospholipid Metabolism
2.3.1. Lipidomic Analysis of Phospholipids
Eight plasma samples of patients with psoriasis vulgaris, eight patients with psoriasis arthritis,
and eight plasma samples from a control group were used to estimate phospholipid profiles of each
group. Total lipids from all plasma samples were extracted by a modified Folch method [33]. The total
amount of phospholipid (PL) was quantified with a phosphorus assay and performed according to
Bartlett and Lewis [34]. The phospholipid profile was characterized by Hydrophilic interaction liquid
chromatography (HILIC-LC)-MS performed on an UPLC system (Agilent 1290, Santa Clara, CA, USA)
coupled to a quadrupole time of flight mass spectrometer (Agilent, QTOF 6540). We have described
this method in details previously [35]. Phospholipid molecular species were identified according
to the typical fragmentation pathways [36]. The relative abundance of each ion was calculated by
normalizing the area of each extracted ion chromatogram peak to the area of an internal standard.
2.3.2. Phospholipid Profile
We analyzed the results obtained for a plasma phospholipid profile of both groups of psoriatic
patients versus healthy volunteers using a Partial least squares-discriminate analysis (PLS-DA) and
variable importance in projection (VIP) for the estimation of the importance among each variable,
which were driving the separation of examined groups (MetaboAnalyst version 3.0) [37].
2.3.3. Determination of Phospholipid and Free Fatty Acids Profile
Fatty acids were determined as fatty acid methyl esters by gas chromatography using an FID
detector after lipid fraction isolation by Folch extraction and a thin layer chromatography technique
separation of free fatty acids (FFA) and phospholipids (PL) [38]. Quantitation was achieved by using
an internal standard method (ISTD).
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2.3.4. Determination of Enzymes Metabolizing Phospholipids
Phospholipase A2 (PLA2—EC.3.1.1.4) activity was measured spectrophotometrically by using
a PLA2 Assay Kit (No. 765021, Cayman Chemical Company, Ann Arbor, MI, USA), according to kit
instructions [39].
PAF acetylhydrolase (PAF-AH—EC.3.1.1.47) activity was measured spectrophotometrically by
using the Cayman's PAF Acetylhydrolase Assay Kit (No. 760901, Cayman Chemical Company,
Ann Arbor, MI, USA), according to kit instructions [40].
Cyclooxygenase 1 and 2 (COX-1/2—EC.1.14.99.1) activities were measured spectrophotometrically
by using a commercial assay kit (Cayman Chemical Company, Ann Arbor, MI, USA) [41].
For distinguishing COX-1 activity from COX-2 activity, the specific COX-1 inhibitor SC-560 was used [42].
2.4. Lipid Peroxidation
Products of phospholipid fragmentation (low molecular aldehydes) were measured by GC/MS
in plasma using the selected ion monitoring (SIM) mode while the O-PFB-oxime or O-PFB-oxime-TMS
derivatives were measured by using minor modifications of the method of Luo et al. [43]. The used
ions were as follows: m/z 333.0 and 181.0 for 4-HNE-PFB-TMS, m/z 204.0.
The determination of products of phospholipid cyclization (total F2-isoprostanes (8-isoPGF2α)
and A4/J4-neuroprostanes (NPs)) were based on methods of Coolen and Fam [44,45]. 8-isoPGF2α
was analyzed in a negative-ion mode using the MRM mode: m/z 353.2→193.1 (for 8-isoPGF2α) and
357.2→197.1 (for 8-isoPGF2 α-d4) while NPs used the ion monitoring (SIM) mode in the m/z 357.0 as
a series of peaks.
2.5. Estimation of the Endocannabinoid System
The LC-MS/MS method was used for the quantification of the levels of endocannabinoids
in plasma [46]. Endocannabinoids were analyzed in positive-ion mode using the MRM mode
(Shimadzu LCMS 8060, Shimadzu, Kioto, Japan). Transitions of the precursor to the product ion
was as follows: m/z 348.0→62.15 for AEA, m/z 379.0→269.35 for 2-AG, m/z 356.0→63.05 for AEA-d8,
m/z 387.0→294.0, m/z for 2-AG-d8, and m/z 430.0→66.0 for OEA-d4.
FAAH (fatty acid amide hydrolase) (EC.3.5.1.99) activity was assessed according to the procedure
described by Siegmund [47] following the releasing of m-nitroaniline (m-NA) from decanoyl
m-nitroaniline at 410 nm.
MAGL (monoacylglycerol lipase) (EC.3.1.1.23) activity was assayed following the release of
5′-thio-2-nitrobenzoic acid from 340 nm [48].
The expression of cannabinoid receptors such as CB1, CB2, and GPR55 was estimated using
Western blot analysis (details are given below).
2.6. Protein Modifications
Determination of Protein Oxidative Modifications
Protein oxidative modifications in plasma were estimated according to the tryptophan and
protein carbonyl levels. To analyze tryptophan levels, samples were diluted in 0.1 mol/L
H2SO4 (1:10) and fluorescence emission/excitation at 325 nm/420 nm and 288 nm/338 nm,
respectively, was measured [49]. All results were normalized for 1 milligram of protein.
The levels of protein carbonyl groups were determined spectrophotometrically (370 nm) using
2,4-dinitrophenylhydrazine [49] and was expressed as nmoles of carbonyl groups per mg protein.
The amounts of 4-hydroxynonenal (4-HNE) protein adducts were measured using a genuine
ELISA method and using an anti-4-HNE-His murine monoclonal antibody (anti-4-HNE-His murine
monoclonal antibody, clone 4-HNE 1g4, curtesy of Prof. Georg Waeg from the University of Graz)
along with a goat anti-mouse antibody (Dako, Carpinteria, CA, USA) as primary and secondary
Cells 2018, 7, 159 6 of 18
antibodies [50]. The concentrations of 4-HNE–protein adducts were normalized for 1 milligram
of protein.
2.7. Expression of Pro-Apoptotic and Anti-Apoptotic Proteins in the Cells
The expression of caspase-8, caspase-9, caspase-3, p53, Bcl2, cytochrome c was estimated using
Western blot analysis (details are given below).
2.8. Pro-Inflammatory Factors
The expression of IL-6 and IL-17 in granulocytes as well as NF-κβ and TNF-α in plasma was
estimated by using Western blot analysis (details are given below).
2.9. Western Blot Analysis
Western blot analysis of protein expression was performed according to Eissa and Seada [51].
The analysis was performed on samples of randomly selected healthy subjects (n = 8) and patients with
psoriasis vulgaris (n = 16) and psoriatic arthritis (n = 8). IL-6 and IL-17 were determined in plasma,
CB1/2 and GPR55 were estimated in granulocyte membrane fraction, and NF-κβ, TNF-α, Nrf2, Keap1,
Bach1, KAP1, p62, p21, HO-1, p53, Bcl2, cyt c, caspase 3, 8, and 9 were estimated in granulocyte cytosol.
β-actin and Na+/K+-ATPase (for cytosolic and membrane fractions, respectively) were used as internal
loading controls. Samples were electrophoretically separated on 10% gels, transferred to 0.2 µm
pore-sized nitrocellulose, and incubated overnight with primary antibodies against: Bach1, HO-1,
caspase-9, p21, KAP1, GPR55, IL-17 (host: rabbit) and NF-κβ, TNF-α, p62, caspase-3, IL-6, β-actin,
and Na+/K+-ATPase (host: mouse) that were purchased from Sigma-Aldrich, (St. Louis, MO, USA).
Primary antibodies against: Keap1 (host: goat), cyt-c, Bcl2, p53, caspase-8 (host mouse), CB1, CB2,
and Nrf2 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Next, membranes
were incubated for 2 h with alkaline phosphatase secondary IgG antibody against a corresponding
primary antibody (Sigma-Aldrich, St. Louis, MO, USA). Protein bands were visualized using the
BCIP/NBT Liquid substrate system (Sigma-Aldrich, St. Louis, MO, USA), which was determined
using the VersaDoc System and Quantity One software (Bio-Rad Laboratories Inc., Hercules, CA, USA).
The results are expressed as a percentage of the expression determined in control cells.
2.10. Statistical Analysis
Data obtained in the current study were expressed as mean ± SD. For comparisons between
groups, the chi-square test was used for categorical variables. The normal distribution of quantitative
data was verified by using the Kolmogorov-Smirnov test with corrections performed using the Lilliefors
test and the Shapiro-Wilk test. To compare differences between the groups, the Mann-Whitney U test
and Kruskal-Wallis test were used. For the comparison of dependent variables, Friedman’s test was
used with an adjusted Conover post-hoc test. A p-value of <0.05 was considered statistically significant.
All statistical analyses were performed by using Stata/IC 13.0 (StataCorp, College Station, TX, USA).
3. Results
3.1. Redox Balance
The onset of psoriasis promoted the formation of oxidative stress both in plasma and in
granulocytes of patients with both forms of psoriasis: psoriasis vulgaris (Ps) and psoriatic arthritis (PsA)
(Table 1). Namely, both forms of psoriasis were associated with a significant increase in granulocyte XO
and NADPH oxidase activity and with a decrease of the activity/level of protein antioxidants (TrxR
and Trx) and of low molecular antioxidants (GSH, vitamin C, and vitamin E) in plasma. Vitamin A
levels were significantly decreased only in PsA and GSH-Px activity was decreased only in Ps patients
while Cu,Zn-SOD activity was significantly higher in the plasma of Ps patients.
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Table 1. The levels of oxidant and antioxidant parameters in plasma or granulocytes* from healthy
subjects (n = 34) and patients with psoriasis vulgaris (n = 68) and psoriatic arthritis (n = 34).
Analyzed Parameters Healthy Subjects Psoriasis Vulgaris Psoriatic Arthritis
XO* U/mg protein 18.8 ± 2.5 30.1 ± 5.3 a 32.71 ± 5.73 a
NADPH oxidase* U/µg protein 2.25 ± 0.28 3.21 ± 0.55 a 3.92 ± 0.71 a
Cu,Zn-SOD U/mg protein 3.91 ± 0.51 4.72 ± 0.81 a 4.12 ± 0.53 x
GSH-Px mU/mg protein 2.16 ± 0.47 1.86 ± 0.45 a 2.17 ± 0.63 x
GSSG-R mU/mg protein 0.73 ± 0.13 0.71 ± 0.14 0.68 ± 0.16
Trx µg/mg protein 6.45 ± 0.92 5.17 ± 0.98 a 3.20 ± 0.89 a,x
TrxR U/mg protein 0.97 ± 0.22 0.56 ± 0.17 a 0.55 ± 0.13 a
GSH nmol/mL 9.54 ± 1.24 6.35 ± 1.06 a 6.19 ± 0.65 a
Vitamin C nmol/mL 41.79 ± 8.69 28.22 ± 9.60 a 22.82 ± 5.05 a,x
Vitamin E nmol/mL 1.01 ± 0.24 0.79 ± 0.20 a 0.80 ± 0.15 a
Vitamin A pmol/mL 248.6 ± 22.7 228.8 ± 32.9 213.6 ± 35.2 a
a p < 0.05 when compared with healthy subjects. x p < 0.05 when compared with patients with psoriasis vulgaris.
Changes at the protein antioxidant levels were also accompanied by changes in the expression of
the transcription factor Nrf2 in granulocytes, which is responsible for the transcription of anti-oxidative
proteins. This was shown in Figure 1. Significant increases in Nrf2 and its target protein HO-1 in
granulocytes of Ps and an increase in Nrf2 accompanied by a decrease in HO-1 in granulocytes of PsA
patients were observed. The level of the granulocyte cytosolic Nrf2 inhibitor, Keap1, was increased in
both Ps and PsA while the nuclear inhibitor, Bach1, was reduced in PsA patients. However, the Nrf2
activators KAP1, p21, and p62 were enhanced in both types of psoriasis.
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Figure 2. (A) Partial least squares-discriminate analysis (PLS-DA) plot of the phospholipid species and
relative abundance determined by HILIC-LC-MS in the plasma of healthy people and both groups
of psoriatic patients. The red triangles indicate healthy subjects (n = 34) while the green and blue
crosses represent patients with psoriasis vulgaris (n = 68) and psoriatic arthritis (n = 34), respectively.
(B) Graphical presentation of the regulation of phospholipids with VIP score ≥1, which differentiate
healthy subjects and patients with psoriasis vulgaris and psoriatic arthritis.
3.3. Fatty Acids Profile
Changes in phospholipid profiles observed in plasma of Ps and PsA patients were associated
with changes in fatty acids composition (Table 2). Phospholipid LA (18:2) and LA (18:3) as well as free
AA (20:4) and DHA (22:6) levels were significantly decreased in Ps and PsA compared with healthy
subjects and, additionally, these fatty acid levels were significantly reduced in PsA compared to Ps.
Furthermore, phospholipid AA (20:4) and DHA (22:6) levels were significantly lowered in PsA if
compared with a healthy control.
Activities of all enzymes participating in phospholipid metabolism (PLA2, PAH-AH, COX-1,
COX-2) were significantly increased in both diseases and additionally were significantly higher in the
plasma of Ps than PsA patients.
Table 2. The level of phospholipids, free fatty acids, and the activity of the enzymes that metabolize
phospholipids and lipid mediators in plasma from healthy subjects (n = 34) as well as patients with
psoriasis vulgaris (n = 68) and psoriatic arthritis (n = 34).
Analyzed Parameters Healthy Subjects Psoriasis Vulgaris Psoriatic Arthritis
Phospholipid LA (18:2) µmol/mL 1.45 ± 0.21 1.24 ± 0.27 a 1.11 ± 0.23 a,x
Phospholipid LA (18:3) µmol/mL 29.95 ± 6.81 26.21 ± 7.96 a 24.04 ± 7.82 a
Phospholipid AA (20:4) µmol/mL 792.7 ± 124.9 739.6 ± 131.5 712.6 ± 143.9 a
Phospholipid DHA (22:6) µmol/mL 292.4 ± 65.2 267.0 ± 71.4 253.5 ± 73.3 a
Free LA (18:2) nmol/mL 17.46 4.83 16.13 ± 5.31 15.09 ± 5.04
Free AA (20:4) nmol/mL 1.51 ± 0.32 1.32 ± 0.41 a 1.09 ± 0.36 a,x
ree DHA (22:6) nmol/mL 1.73 0.41 1.43 ± 0.45 a 1.20 ± 0.44 a,x
PLA2 nmol/mL/min 9 18 0.919 12.05 ± 1 59 9.98 ± 1.48 a,x
PAH-AH nmol/ L/ in 30.27 ± 2.12 56.56 ± 10.49 a 48.94 ± 7.53 a,x
COX-1 nmol/mL/min 0.43 ± 0.07 0.63 ± 0.13 a 0.54 ± 0.09 a,x
COX-2 nmol/mL/min 0.17 ± 0.03 0.52 ± 0.14 a 0.44 ± 0.09 a,x
a p < 0.05 when co pared with healthy subjects; x p < .05 when compared with patients with psoriasis vulgaris.
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3.4. Lipid Peroxidation
Changes in PUFA levels were accompanied by enhanced levels of lipid oxidative fragmentation
products such as 4-HNE as well as products of phospholipid oxidative cyclization such as
8-isoprostanes and neuroprostanes observed in plasma of Ps and PsA patients but only low molecular
aldehyde levels were significantly higher in Ps than in PsA patients (Table 3). Moreover 4-HNE-protein
adduct levels were significantly increased in the plasma of patients suffering from both types of disease
but were higher in Ps than PsA patients.
Table 3. The level of protein and phospholipid oxidative modification products in plasma from healthy
subjects (n = 34) and patients with psoriasis vulgaris (n = 68) and psoriatic arthritis (n = 34).
Analyzed Parameters Healthy Subjects Psoriasis Vulgaris Psoriatic Arthritis
4-HNE nmol/mL 8.90 ± 3.71 15.36 ± 7.81 a 11.01 ± 1.86 a,x
Isoprostanes pmol/mL 1.61 ± 0.37 3.41 ± 0.79 a 3.84 ± 0.99 a
Neuroprostanes pmol/mL 2.93 ± 0.61 6.56 ± 1.20 a 6.42 ± 1.09 a
Tryptophan U/mg protein 35.12 ± 5.36 26.84 ± 6.21 a 24.79 ± 6.63 a
HNE–protein pmol/mg protein 15.24 ± 3.62 21.59 ± 4.26 a 17.45 ± 4.16 a,x
a p < 0.05 when compared with healthy subjects. x p < 0.05 when compared with patients with psoriasis vulgaris.
3.5. Endocannabinoid System
The development of Ps and PsA also affected the functioning of the endocannabinoid system
(Figure 3). In the plasma of Ps and PsA patients, there were significantly higher levels of AEA and 2-AG
than in healthy subjects (Figure 3C). The activity of granulocyte enzymes degrading endocannabinoids
including FAAH and MAGL was also increased in patients (Figure 3B). The expression of cannabinoid
receptors was also enhanced in patient’s granulocytes but CB1 was higher in PsA patients while
CB2 was higher in Ps patients. The GPR55 expression was equally increased in both groups of
psoriatic patients.
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3.6. Protein Modifications
Both Ps and PsA led to oxidative damage of the granulocyte cellular proteins (Figure 4), which was
indicated by a significant increase in the level of protein dityrosine and enhanced caspase activities.
Caspase-3, caspase-8, caspase-9, and cyt-c expression was significantly higher in psoriatic patients
when compared with the control. Expression is also higher in Ps than in PsA while Bcl2 was
significantly lower in Ps or PsA than in healthy control granulocytes.
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Figure 4. The level of pro-apoptotic proteases (caspase-8, caspase-9, caspase-3) and proteins involved
in cell death (Bcl2 and cytochrome c) in granulocytes from healthy subjects (n = 8) and patients with
psoriasis vulgaris (n = 16) and psoriatic arthritis (n = 8). a p < 0.05 when compared with healthy subjects.
x p < 0.05 when compared with patients with psoriatic vulgaris.
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3.7. Pro-Inflammatory Mediators
Ps and PsA were characterized by increased levels of pro-inflammatory markers (Figure 5).
Plasma IL-6 level was significantly higher in Ps and PsA patients than in a control, which is also higher
in PsA when compared to Ps levels. On the other hand, IL-17 was enhanced only in PsA patients.
However, NF-κβ and TNF-α were significantly, but equally, increased in granulocytes of both Ps and
PsA patients in comparison to values obtained for granulocytes of the healthy control subjects.
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Figure 5. The levels of interleukins and pro-infla atory ediators in plasma or granulocytes* from
healthy subjects (n = 8) and patients with psoriasis vulgaris (n = 16) and psoriatic arthritis (n = 8).
a p < 0.05 when compared with healthy subjects. x p < 0.05 when compared with patients with
psoriasis vulgaris.
4. Discussion
Psoriasis has a complex autoimmune pathogenesis resulting from inflammatory pathophysiology
and an imbalance in the redox system homeostasis, which leads to persistent oxidative stress [15].
An important role in the pathogenesis of psoriasis is also attributed to genetic factors. It is believed that
some mutations may lead to an abnormally increased activity of the immune system and, consequently,
to increased inflammation and accompanying oxidative stress [15].
An important pathophysiological component of oxidative stress observed in patients with
psoriasis vulgaris (Ps) and psoriatic arthritis (PsA) in our study were disturbances in phospholipid
metabolism. The results of the current study indicate changes in the metabolism of PUFAs leading to
disturbances in the biosynthesis of different lipid mediators including endocannabinoids generated as
a result of the action of phospholipases [12] among which the activity of phospholipase A2 was found
to be significantly higher in Ps then in PsA. Therefore, elevated levels of two main endocannabinoids
anandamide (AEA) and 2-arachidonoylglycerol (2-AG) were observed in patients with both forms of
psoriasis despite elevated activity of enzymes degrading these endocannabinoids (FAAH and MAGL).
These findings suggest that higher levels of endocannabinoids are caused by their enhanced generation.
Endocannabinoids, which are the agonists of specific protein G-coupled receptors, are thought to have
pleiotropic effects depending on the type of the receptor activated [10]. In our patients, the expression
of the receptor GPR55 was elevated in both forms of psoriasis while the expression of the receptor
CB2 was elevated only in Ps in contrast to the CB1 receptor, which was increased only in PsA patients.
Overexpression of endocannabinoids may be an attempt of the organism/inflammatory cells to
prevent pathological conditions occurring during the progression of psoriasis. Previous in vitro
studies suggested that endocannabinoids themselves may cause the inhibition of the NF-κB pathway,
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which may exert anti-inflammatory effects [52]. However, the level of pro-inflammatory factors and the
intensity of oxidative stress were found to be so pronounced in the course of psoriasis (both forms) that
the activities of endocannabinoids were unable to control such a cellular and systemic inflammatory
character of oxidative stress. Consequently, an elevated expression of NF-κβ and the product of its
transcription activity, TNF-α, were observed in granulocytes of both Ps and PsA. This transcription
factor takes part in both inflammation and redox balance regulation. The NF-κB enhances pro-oxidative
activity through the expression of NADPH oxidase, xanthine oxidase, and iNOS [53]. Our study
also showed enhanced activity of NADPH and xanthine oxidases to a similar degree in both types
of psoriasis, which was also the case of NF-κB. Activation of pro-oxidant enzymes revealed in
granulocytes of psoriatic patients indicates that these cells undergo an oxidative burst and generates
ROS in the course of both Ps and PsA. The available literature data also indicate enhanced pro-oxidative
conditions in Ps [19], but there is a lack of studies focused on PsA, which was done in our study.
Since the physiological redox balance results from an equilibrium between pro-oxidants and
antioxidants, the antioxidant capacity of plasma obtained from psoriatic patients has also been
assessed to reflect systemic oxidative stress. Notably, the Cu,Zn-SOD activity has been shown to
be increased in the plasma of both groups of psoriatic patients most likely as a response to increased
superoxide anion generation by NADPH and xanthine oxidases that is metabolized by superoxide
dismutases [54]. Moreover, capacities of antioxidant systems such as glutathione (glutathione
peroxidase-GSH-glutathione reductase) and thioredoxin-dependent reductase (TrxR-Trx), as well
as levels of supporting small molecular antioxidants including vitamins A, E, and C were found to
be decreased in our patients. Earlier reports indicated a lack of changes or an increase in vitamins
A and E levels [19], but these parameters are strongly influenced by eating habits and the severity
of the disease. As seen in the current study, previous studies also showed lower activity of GSH-Px
in plasma and granulocytes of psoriasis patients [19] and current knowledge suggests that it may
result from mutations in the genes of these antioxidants [54]. However, other studies have shown that
an enhanced level of NF-κβ may promote transcription of antioxidants including SOD, GSH-Px, and
HO-1 [53]. This is consistent with the elevated activity of Cu,Zn-SOD and enhanced expression of
Trx and HO-1 observed in the current study in patients with psoriasis vulgaris. Enhanced expression
of HO-1 and other antioxidant proteins may also result from modulation of gene expression by the
transcription factor Nrf2 [23]. The regulation of Nrf2 activity is related to the influence of its inhibitors
and activators [22,55]. In physiological conditions, Nrf2 is coupled to the cytosolic inhibitor Keap1,
which directs this transcription factor to ubiquitination and degradation and, in this way, prevents
its translocation to the nucleus and initiation of the transcription process [22]. Increased Keap1 levels
observed in psoriasis should mean stronger Nrf2 degradation. However, Keap1 has several critical
cysteine residues that may be modified by ROS and by the lipid peroxidation product 4-HNE [56,57].
The levels of 4-HNE were revealed as increased in psoriatic patients, which might prevent Nrf2
and Keap1 binding [58]. Furthermore, the Nrf2 activators levels (KAP1, p62, and p21) were also
increased in granulocytes of psoriatic patients, which indicate enhanced activation of Nrf2. Additional
confirmation of the role of oxidative stress in the course of Ps are the results of clinical trials in which
antioxidant supplementation resulted in a significant improvement in the general status of psoriatic
patients [59]. So far, systemic changes at the transcription level have not been studied and only the
local reduction of Nrf2 transcriptional activity in the skin of psoriasis patients has been found [24].
This occurred despite the markedly lower levels of Nrf2 pathway inhibitors such as Bach1 and Keap1
in PsA than in Ps patients indicating the role of activator KAP1 revealed at a significantly reduced level
in granulocytes of PsA patients if compared to Ps. However, the lack of expected increase of HO-1
level in the granulocytes of patients with PsA vs. Ps suggests that, despite the increased pro-oxidative
conditions, there is no enhancement of the anti-oxidative response in the inflammatory cells of these
patients. In addition, HO-1 shows a direct antioxidant effect promotes more intense oxidative stress in
PsA than in Ps patients.
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The pro-oxidative conditions observed in both forms of psoriasis should result in ROS
reactions with nucleophilic compounds including lipids and proteins, which causes their oxidative
modifications. Particularly susceptible to oxidative modifications are PUFAs, which are either bound
to phospholipids or as free molecules, in bio-membranes and are metabolized in ROS-dependent and
in enzyme-catalyzing reactions [4]. The results obtained in our study have shown that levels of PUFAs
decrease in both forms of psoriasis but more in the case of PsA, which had more pronounced onset of
oxidative stress, as discussed earlier. Similar systemic alterations of the PUFA metabolism were also
observed in other inflammatory diseases such as rheumatoid arthritis (RA) [60,61]. The ROS-dependent
peroxidation of PUFAs generates a broad range of products including compounds produced during
oxidative cyclization as well as fragmentation [6,62]. The 8-isoprostanes and neuroprostanes are
generated in situ from esterified PUFAs (mainly from AA and DHA, respectively) being released by
phospholipases including PLA2 and PAF-AH [63]. The activity related to this was also increased
in our psoriatic patients but more in the case of Ps than PsA. The increased activity of PLA and
PAF-AH may promote the release of 8-isoprostanes and neuroprostanes, which was confirmed by
the significantly elevated levels of these compounds in the plasma of patients with both forms of
psoriasis. That might further lead to the vicious pathophysiological circle because 8-isoprostanes act as
signaling molecules activating the CD11b/CD18 and CD11c/CD18 receptors that play a key role in
neutrophil activation and migration [64]. Another relevant pathway involving oxidative metabolism
of PUFAs such as arachidonic acid is by cyclooxygenases. The activity of this was increased in the
case of psoriasis. Since the activation of cyclooxygenases leads to the generation of pro-inflammatory
eicosanoids, increased COX-1/2 activity may contribute to their over-generation in similar ways as
observed for other inflammatory diseases [65].
The results obtained in this study also indicate enhanced plasma levels of other lipid peroxidation
end products including reactive aldehydes generated during PUFAs fragmentation (4-HNE) with
significantly higher increases in the plasma of Ps patients if compared to patients with PsA. Observed
increases in the 4-HNE levels reflect non-enzymatic peroxidation of LA and AA [7] reducing their
levels, which was found in the plasma of psoriatic patients. This reactive aldehyde may diffuse to
longer distances than ROS and behave as a secondary messenger of free radicals that can propagate
oxidative damages especially if bonded to proteins. This aldehyde reacts with the nucleophilic cysteine,
lysine, and histidine residues of proteins to form stable covalent adducts [66]. Exposure of biological
systems to these electrophiles can modify a subset of proteins, which generates intramolecular covalent
adducts with histidine in both Ps and PsA. It is known that 4-HNE creating protein adducts could
decrease biological activity of GSH-Px and GSH along with Keap1 [67]. However, it was also shown
that 4-HNE, at least in vitro, reduces the oxidative burst of granulocytes interacting with proteins
involved in that process [62]. Therefore, this particular aldehyde might also act in a positive way
by attenuating oxidative activities of the inflammatory cells in psoriasis, which is similar to its
multiple effects in cardiovascular diseases and the metabolic syndrome, which are known as psoriatic
comorbidities [58,68].
Along with the actions of lipid peroxidation products as signaling molecules, free DHA may also
bind to GPR120 and inhibit NF-κβ, which consequently reduces the severity of inflammation [69].
However, a decrease of free DHA has been observed for our psoriatic patients. In PsA patients,
this was more pronounced when accompanied by an increase in the level of NF-κβ and inflammatory
conditions, which was confirmed by an enhanced level of pro-inflammatory cytokines (Il-6, Il-17,
and TNF-α). This may offer an explanation for the activity principles of the effective diets rich in DHA
applied for the integrative treatment of psoriasis [70].
Protein modifications observed in psoriasis could lead to impaired functions of targeted
cellular proteins, which causes apoptosis through receptor and mitochondrial pathways. Psoriatic
patients showed an increase in TNF-α expression, which could promote the activation of the death
receptor-mediated pathway as verified by a significant increase of the expression of caspase-8 revealed
for granulocytes in both forms of psoriasis. This caspase can directly activate executioner caspase-3,
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but may also be indirectly involved in the mitochondrial pro-apoptotic pathway. This results in
caspase-9 activation [71], which was more expressed in Ps than in PsA likely because of the strong
influence of caspase-8 from the external pathway. However, caspase-8 can also activate the transcription
factor, NF-κB, which is a product of transcriptional activity of TNF-α activated death receptors [72].
The enhanced expression of the executioner caspase-3 was observed in both forms of psoriasis but
was significantly higher in Ps than in PsA. Moreover, granulocytes from patients with psoriasis were
also characterized by changes in the mitochondrial pathway including a decrease of the anti-apoptotic
protein Bcl-2 that could lead to a release of cytochrome c from mitochondria that binds APAF1 and
subsequently induces caspase-9, which results in the activation of caspase-3 and, thus, executes cell
death [73]. Lastly, it should be mentioned that activation of cannabinoid receptor CB2 could lead to
enhanced biosynthesis of ceramides and cause overexpression of protein p38 and transcription factor 4,
which consequently results in cell apoptosis [74]. This may explain a stronger expression of apoptotic
pathways in inflammatory granulocytes obtained from Ps than from PsA patients.
5. Conclusions
This study revealed changes in the redox balance and results in modifications of phospholipid
metabolism in psoriatic patients, which is associated with significant differences in several cell signaling
pathways relevant for the pathophysiology of psoriasis. Oxidative stress was found as a common
element of both Ps and PsA, but inflammatory cells of these patients responded to it in different
ways. Granulocytes obtained from patients with Ps showed higher activation of the Nrf2 pathway and
expression of CB2 that could attenuate oxidative stress and act as an anti-inflammatory process but is
also indicated as more enhanced oxidative phospholipid modifications. However, more pronounced
phospholipid enzymatic metabolism in PsA than in Ps patients was observed. Thus, changes in
the redox system and the metabolism of granulocyte phospholipids in the course of psoriasis have
a much more complex character than in other inflammatory diseases and may also be attributed to
genetic factors.
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